AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 91 min read$DNLI

Chin Peter Scott sold $37K of DNLI

Chin Peter Scott (Chief Medical Officer) sold 1,654 shares of Denali Therapeutics Inc. (DNLI) at $22.29 on 2026-09-04.

Original reporting
SEC EDGAR · Chin Peter Scott
Published Sep 9, 2026, 8:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$DNLI
Bearish
medium confidence
Mentioned
$DNLI
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DNLIBearishLow
01

Why it matters

The transaction is modest and unlikely to affect the stock beyond a brief dip.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical data could offset any negative sentiment from the sale.

Relevance 3/10Novelty 4/10Timing: today

Background

Form 4 filing by Denali Therapeutics' Chief Medical Officer discloses a small open‑market sale.

Company-level read

Ticker impact

$DNLIBearishMedium confidence
Context

Chief Medical Officer sold 1,654 shares for $36,867, reducing his stake to 204,538 shares.

Expected impact

Potential slight downward pressure in the short term.

Evidence & confidence

Sale amount is under $50k and represents a small percentage of holdings; market typically views such small CMO sales as routine.

Market effects

Sector

No significant impact on biotech sector.

Regional

Limited to US biotech investors.

Global

Minimal.

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not reflect lack of confidence.

Key entities

  • Company
    Denali Therapeutics Inc.

    Biotech firm developing therapies for neurodegenerative diseases.

  • Executive
    Chin Peter Scott

    Chief Medical Officer of Denali Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

DNLI insider trading history →

Related articles

AUG 13
$DNLIMedAI 8/10

Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript

Denali Therapeutics (DNLI) reported Q2 2026 net product revenue of $3.6 million from the first full quarter of AVLAYAH in the US. It guided Q3 revenue to $10 million to $12 million and said pro forma cash and securities were $1.1 billion after a $195 million priority review voucher sale. R&D was $97.0 million; net loss was $127.6 million.

fool.com6 min
AUG 6
$DNLIMed

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Denali Therapeutics Inc. (DNLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights • Strong first full quarter of AVLAYAH™ (tividenofusp alfa-eknm) launch generated $3.6 million in net product revenue • Advanced TransportVehicle™ portfolio with two Alzheimer’s

SEC EDGAR 8-K6 min
JUL 28
$DNLIMed

Denali Therapeutics Inc. (DNLI): Completion of Acquisition or Disposition of Assets

Denali Therapeutics Inc. (DNLI) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. dnli-20260727 0001714899 FALSE 0001714899 2026-07-27 2026-07-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

SEC EDGAR 8-K2 min
JUL 14
$BIIBMed

New experimental Alzheimer's drug shows potential after study shows slower cognitive decline

Biogen reported at the Alzheimer’s Association International Conference that its experimental antisense drug diranersen, given via spinal injection, slowed cognitive decline in a subset of about 400 participants with mild cognitive impairment or mild Alzheimer’s. In one lowest-dose test, results showed a 26% reduction in decline versus placebo. Biogen plans a larger study; side effects included injection pain and temporary confusion.

fortune.com6 min
NOV 3
$ASPEMedAI 8/10

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $18.0M of ASPE (indirect holdings)

ARCH Venture Fund X, L.P. purchased 1,200,000 indirectly-held shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($18.00M total) on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).

SEC EDGAR1 min